Press release
Duchenne Muscular Dystrophy Treatment Market Demand is Increasing in Most Part of World 2024
Specific guidance for drug development for Duchenne muscular dystrophy drugs published by the U.S. FDA in 2015 is expected to accelerate the new drug development for treatment of a disorder. Moreover, new approaches such as utrophin modulation approach for the treatment of Duchenne muscular dystrophy are expected to launch in the market during the forecast period. For instance, Summit Therapeutics plc. is evaluating ezutromid in phase II clinical trials which has received orphan drug designation and fast track approval from U.S. FDA.Get access to full summary @: http://www.persistencemarketresearch.com/market-research/duchenne-muscular-dystrophy-treatment-market.asp
Duchenne muscular dystrophy (DMD) is one of the most common types of muscular dystrophy, which is an X-linked inherited genetic disorder characterized by gradual skeletal muscle weakness. According to NHS, in every year 100 boys are born with Duchenne muscular dystrophy in the U.K. As per DMD surveillance report by Center for Disease Control and Prevention (CDC), 349 new cases of Duchenne muscular dystrophy were reported in 2010 in the U.S. Duchenne muscular dystrophy usually affects male child and first signs and symptoms of the disease are observed at the age of 2-3 years.
Duchenne muscular dystrophy worsens quickly which results in loss of ability to walk and eventually causes death within 20-30 years of age. Currently there is no curative treatment for Duchenne muscular dystrophy however symptomatic treatment approaches such as pain alleviating drugs and steroids to slow down the progression of disease are recommended by majority of physicians. Treatment is mainly aimed to maximize the quality of life.
Continuous research on gene therapy, exon skipping drugs and stem cell therapy for the treatment of Duchenne muscular dystrophy is expected to fuel the global market for Duchenne muscular dystrophy treatment market over the forecast period. BioMarin Pharmaceutical Inc. is developing exon skipping drug Drisapersen which is currently being evaluated in phase III clinical trial. In 2014, PTC Therapeutics International Limited obtained orphan drug designation and conditional approval for Translarna–first ever gene therapy for treatment of Duchenne muscular dystrophy, in Europe. However, low treatment seeking rate due to delayed diagnosis and fast prognosis of a disorder is the major factor limiting the growth of global Duchenne muscular dystrophy treatment market.
The global market for Duchenne muscular dystrophy treatment is segmented on basis of product type, end user and geography: Segmentation by Treatment Type: Pain Management drugs, Corticosteroids, Prednisolone, Prednisone, Deflazacort. Segmentation by End User: Hospitals, Clinics, Home Care Settings.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12475
Collaborations between key players involved in development of drugs for Duchenne muscular dystrophy would increase the pace of new drug development for the disease. By product type, the global market for Duchenne muscular dystrophy treatment has been classified into pain management drugs and corticosteroids. Corticosteroids product type segment is expected to hold maximum share in global Duchenne muscular dystrophy treatment market.
Based on end user, the global Duchenne muscular dystrophy treatment market has been classified as hospitals, clinics and home care settings. Hospitals end user segment is expected to hold maximum share in the global market owing to increasing rate of hospitalization for DMD.
On the basis of regional presence, global Duchenne muscular dystrophy treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America will continue to dominate the global Duchenne muscular dystrophy treatment market due to high prevalence of the disease. Europe is expected to hold second largest market share in global market. Increasing R&D activities in the DMD area is expected to bring huge growth of global market during the forecast period.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/12475
Some of the major players operating in global Duchenne muscular dystrophy treatment market are PTC Therapeutics, Summit Therapeutics Plc., Sarepta Therapeutics, BioMarin Pharmaceutical Inc., Pfizer Inc., (Pharmacia & Upjohn LLC) and others. Companies are involved in collaboration agreements for R&D in order to exploit maximum potential.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Treatment Market Demand is Increasing in Most Part of World 2024 here
News-ID: 614310 • Views: …
More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market
The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and…

Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts.
Forged automotive components are critical to…

Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the…

Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring…
More Releases for Duchenne
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in the…
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…